Cadrenal Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cadrenal Therapeutics (CVKD).

Price Target Range — 6 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingOutperform# Analysts2Avg. Consensus PT$37Upside to Avg. PT+3824.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Apr 7, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$32→$13
May 16, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$32
Nov 11, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$3→$32
Jun 6, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$45
May 9, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$45
Mar 14, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$45
Dec 18, 2023	Noble Capital Markets	Robert LeBoyer	Initiate	Outperform	$60
Nov 20, 2023	HC Wainwright & Co.	Joseph Pantginis	Initiate	Buy	$45

Analyst Ratings News

PRO
Watching Cadrenal Therapeutics; Zacks Small-Cap Research Gives Stock $17 Price Valuation

Benzinga Newsdesk

PRO
Watching Cadrenal Therapeutics; Zacks Small-Cap Research Gives Stock $25 Price Valuation

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Lowers Price Target to $13

HC Wainwright & Co. analyst Joseph Pantginis maintains Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and lowers the price target from $32 to $13.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $32 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $32 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Adjusts Price Target To $32 (1-15 Reverse Stock Split)

HC Wainwright & Co. analyst Joseph Pantginis maintains Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy, adjusts target to $32 from $3 (1-15 Reverse Stock Split).

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $3 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $3 price target.

Benzinga Newsdesk

Cadrenal Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Cadrenal Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Watching Cadrenal Therapeutics; Zacks Small-Cap Research Gives Stock $17 Price Valuation

PRO
Watching Cadrenal Therapeutics; Zacks Small-Cap Research Gives Stock $25 Price Valuation

PRO
HC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Lowers Price Target to $13

PRO
HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $32 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Adjusts Price Target To $32 (1-15 Reverse Stock Split)

PRO
HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $3 Price Target

People Also Watch

People Also Watch

Cadrenal Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Cadrenal Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWatching Cadrenal Therapeutics; Zacks Small-Cap Research Gives Stock $17 Price Valuation

PROWatching Cadrenal Therapeutics; Zacks Small-Cap Research Gives Stock $25 Price Valuation

PROHC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Lowers Price Target to $13

PROHC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $32 Price Target

PROHC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Adjusts Price Target To $32 (1-15 Reverse Stock Split)

PROHC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $3 Price Target

People Also Watch

People Also Watch

PRO
Watching Cadrenal Therapeutics; Zacks Small-Cap Research Gives Stock $17 Price Valuation

PRO
Watching Cadrenal Therapeutics; Zacks Small-Cap Research Gives Stock $25 Price Valuation

PRO
HC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Lowers Price Target to $13

PRO
HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $32 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Adjusts Price Target To $32 (1-15 Reverse Stock Split)

PRO
HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $3 Price Target